Third, there is still no immune scoring system to stratify the prognosis and guide immunotherapy for GBC based on PD-L1 expression and tumor-infiltrating lymphocytes (TILs), most notably due to the low rate of PD-L1 overexpression. Here, CD274 is linked to neoplasm.